Super Funds Urged To Consider Healthcare Sector For Exceptional Returns

.. IB Australian Bioscience Fund I outperforms ASX200AI 72%  Delivers ~30% annual IRR* Melbourne, Australia 8 April  2013: A LEADING Australasian healthcare fund has generated a unit price of $1.81 for every dollar invested four and a half years ago, prompting its managers to urge superannuation funds to ‘strongly’ consider backing proven managers in the […]

BioScience Managers Expands Asia Pac Presence – Invests $3M in NZ Patient Monitoring Company

(Melbourne) Leading Asia Pacific healthcare fund manager, BioScience Managers Pty Ltd, today announced a $3m investment in innovative New Zealand asthma technology company Nexus6. Nexus6’s SmartInhaler product remotely monitors adherence to asthma treatment regimes, ensuring patients comply with treatment protocols in general use and in clinical trials, giving clinicians transparency over inhaler use and dosage […]

Bioscience Managers Announces First Close on New Healthcare Fund

Top Decile[1] Fund Manager announces first close on second fund First closing at A$55m supported Australian institutions IOOF provides $45m cornerstone Focused on clinical stage healthcare and life sciences firms First investment $3m into ASX Listed Avita (ASX.AVH) Leading Australasian bioscience fund manager, Octa Phillip Bioscience Managers (Bioscience Managers), today announced a successful first close on its […]

Angiotech Founder Joins Union Medtech & Bioscience Managers’ Global Team

Octa Phillip Bioscience Managers provision of management services and support to Union MedTech Plc, the UK listed medical technology investment vehicle, today received a boost with Union Medtech’s announcement of the appointment of Dr William (Bill) Hunter to its board. William Hunter co-founded Angiotech Pharmaceuticals in 1992 while still being a medical student at university.  […]

Leading Fund Manager Snares Star Analyst

New look Octa Phillip Bioscience Managers (Bioscience Managers – formerly IB Managers) is looking to create an all-star team with the addition of Starmine top rated analyst Dr Graeme Wald as it progresses towards a first close on its second fund. With its first fund’s performance confirmed in the top decile of global (2008 ex-US) […]